Cargando…

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

BACKGROUND/AIM: Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment. However, treatment with INH is complicated by polymorphisms in the expression of the enzyme system primarily responsible for its elimination, N-acetyltransferase 2 (NAT2), and its associated hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Jin Ah, Kim, Tae-Eun, Lee, Hyun, Jeong, Byeong-Ho, Park, Hye Yun, Jeon, Kyeongman, Kwon, O Jung, Ko, Jae-Wook, Choi, Rihwa, Woo, Hye-In, Koh, Won-Jung, Lee, Soo-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598210/ https://www.ncbi.nlm.nih.gov/pubmed/26491254 http://dx.doi.org/10.2147/DDDT.S87131

Ejemplares similares

Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations
por: Choi, Rihwa, et al.
Publicado: (2017)

Serum Concentrations of Trace Elements in Patients with Tuberculosis and Its Association with Treatment Outcome
por: Choi, Rihwa, et al.
Publicado: (2015)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy
por: Bosch, Luis Ángel Bermúdez
Publicado: (2014)

Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare
por: Masimirembwa, C, et al.
Publicado: (2013)

Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
por: Requena-Méndez, Ana, et al.
Publicado: (2014)

Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis
por: Seo, Wan, et al.
Publicado: (2023)

Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease
por: Kim, Su-Young, et al.
Publicado: (2017)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
por: Kwak, Se Hyun, et al.
Publicado: (2020)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Timing of silicone stent removal in patients with post-tuberculosis bronchial stenosis
por: Eom, Jung Seop, et al.
Publicado: (2013)

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

Clinical significance of smear positivity for acid-fast bacilli after ≥5 months of treatment in patients with drug-susceptible pulmonary tuberculosis
por: Kang, Hyung Koo, et al.
Publicado: (2016)

QuantiFERON-TB Gold In-Tube Assay for Screening Arthritis Patients for Latent Tuberculosis Infection before Starting Anti-Tumor Necrosis Factor Treatment
por: Lee, Hyun, et al.
Publicado: (2015)

The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonist Therapy
por: Jung, Yu Jung, et al.
Publicado: (2015)

Outcomes of Bronchial Artery Embolization for Life-Threatening Hemoptysis in Patients with Chronic Pulmonary Aspergillosis
por: Shin, Beomsu, et al.
Publicado: (2016)

Chronic obstructive pulmonary disease severity is associated with severe pneumonia
por: Eom, Jung Seop, et al.
Publicado: (2015)

Association of ISMav6 with the Pattern of Antibiotic Resistance in Korean Mycobacterium avium Clinical Isolates but No Relevance between Their Genotypes and Clinical Features
por: Kim, Su-Young, et al.
Publicado: (2016)

Treatment of thoracic actinomycosis: A retrospective analysis of 40 patients
por: Song, Jae-Uk, et al.
Publicado: (2010)

Standardized Combination Antibiotic Treatment of Mycobacterium avium Complex Lung Disease
por: Sim, Yun Su, et al.
Publicado: (2010)

Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study
por: Min, Jinsoo, et al.
Publicado: (2022)

Additional role of second washing specimen obtained during single bronchoscopy session in diagnosis of pulmonary tuberculosis
por: Yoo, Hongseok, et al.
Publicado: (2013)

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2020)

Isoniazid and Pulmonary Fibrosis
por: Chung, Chae Uk, et al.
Publicado: (2015)

Warfarin Dosage Response Related Pharmacogenetics in Chinese Population
por: Li, Siyue, et al.
Publicado: (2015)

Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System
por: Wang, Hye-young, et al.
Publicado: (2018)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study
por: Kwon, Yong-Soo, et al.
Publicado: (2015)

Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea
por: Koh, Won-Jung, et al.
Publicado: (2013)

Tracheal Wall Thickening Is Associated with the Granulation Tissue Formation Around Silicone Stents in Patients with Post-Tuberculosis Tracheal Stenosis
por: Eom, Jung Seop, et al.
Publicado: (2013)

Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines
por: Kim, Sollip, et al.
Publicado: (2017)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Molecular analysis of clinical isolates previously diagnosed as Mycobacterium intracellulare reveals incidental findings of “Mycobacterium indicus pranii” genotypes in human lung infection
por: Kim, Su-Young, et al.
Publicado: (2015)

Proposal for a Pharmacogenetic Decision Algorithm
por: Alzghari, Saeed K, et al.
Publicado: (2017)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

Performance evaluation of the Xpert MTB/RIF assay according to its clinical application
por: Huh, Hee Jae, et al.
Publicado: (2014)

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization
por: Ong, Frank S., et al.
Publicado: (2013)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ileb8cbvhvn0skqh6e5sv9jn0j